ESPR
Price
$2.21
Change
-$0.05 (-2.21%)
Updated
Jan 17 closing price
Capitalization
495.94M
39 days until earnings call
VTRS
Price
$11.30
Change
-$0.04 (-0.35%)
Updated
Jan 17 closing price
Capitalization
14.18B
44 days until earnings call
Ad is loading...

ESPR vs VTRS

Header iconESPR vs VTRS Comparison
Open Charts ESPR vs VTRSBanner chart's image
Esperion Therapeutics
Price$2.21
Change-$0.05 (-2.21%)
Volume$2.55M
Capitalization495.94M
Viatris
Price$11.30
Change-$0.04 (-0.35%)
Volume$7.72M
Capitalization14.18B
ESPR vs VTRS Comparison Chart
Loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ESPR vs. VTRS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESPR is a Hold and VTRS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (ESPR: $2.21 vs. VTRS: $11.30)
Brand notoriety: ESPR and VTRS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ESPR: 39% vs. VTRS: 88%
Market capitalization -- ESPR: $495.94M vs. VTRS: $14.18B
ESPR [@Pharmaceuticals: Other] is valued at $495.94M. VTRS’s [@Pharmaceuticals: Other] market capitalization is $14.18B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESPR’s FA Score shows that 0 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • ESPR’s FA Score: 0 green, 5 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, VTRS is a better buy in the long-term than ESPR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESPR’s TA Score shows that 2 TA indicator(s) are bullish while VTRS’s TA Score has 2 bullish TA indicator(s).

  • ESPR’s TA Score: 2 bullish, 3 bearish.
  • VTRS’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, ESPR is a better buy in the short-term than VTRS.

Price Growth

ESPR (@Pharmaceuticals: Other) experienced а -5.56% price change this week, while VTRS (@Pharmaceuticals: Other) price change was -3.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.30%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was -9.85%.

Reported Earning Dates

ESPR is expected to report earnings on May 07, 2025.

VTRS is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.30% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($14.2B) has a higher market cap than ESPR($496M). ESPR YTD gains are higher at: 0.455 vs. VTRS (-9.237). VTRS has higher annual earnings (EBITDA): 3.52B vs. ESPR (-150.11M). VTRS has more cash in the bank: 1.18B vs. ESPR (82.2M). ESPR has less debt than VTRS: ESPR (266M) vs VTRS (18.4B). VTRS has higher revenues than ESPR: VTRS (15.4B) vs ESPR (116M).
ESPRVTRSESPR / VTRS
Capitalization496M14.2B3%
EBITDA-150.11M3.52B-4%
Gain YTD0.455-9.237-5%
P/E RatioN/A238.80-
Revenue116M15.4B1%
Total Cash82.2M1.18B7%
Total Debt266M18.4B1%
FUNDAMENTALS RATINGS
ESPR vs VTRS: Fundamental Ratings
ESPR
VTRS
OUTLOOK RATING
1..100
8258
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10091
PRICE GROWTH RATING
1..100
5159
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (20) in the null industry is in the same range as ESPR (39) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ESPR’s over the last 12 months.

VTRS's Profit vs Risk Rating (100) in the null industry is in the same range as ESPR (100) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ESPR’s over the last 12 months.

VTRS's SMR Rating (91) in the null industry is in the same range as ESPR (100) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ESPR’s over the last 12 months.

ESPR's Price Growth Rating (51) in the Biotechnology industry is in the same range as VTRS (59) in the null industry. This means that ESPR’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for ESPR (100) in the Biotechnology industry. This means that VTRS’s stock grew significantly faster than ESPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ESPRVTRS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 11 days ago
63%
Momentum
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
56%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
87%
Bearish Trend 11 days ago
63%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
85%
Bearish Trend 11 days ago
61%
Advances
ODDS (%)
Bullish Trend 24 days ago
86%
N/A
Declines
ODDS (%)
Bearish Trend 13 days ago
88%
Bearish Trend 13 days ago
64%
BollingerBands
ODDS (%)
N/A
Bullish Trend 11 days ago
61%
Aroon
ODDS (%)
N/A
Bearish Trend 11 days ago
66%
View a ticker or compare two or three
Ad is loading...
ESPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ADNCX15.250.21
+1.40%
American Beacon ARK Transfmt Innov C
PLJMX55.050.59
+1.08%
Putnam Research R6
LGLIX51.450.54
+1.06%
Lord Abbett Growth Leaders I
FPPUX11.760.04
+0.34%
MFS Prudent Investor R4
JAAGX86.170.10
+0.12%
Janus Henderson VIT Enterprise Instl

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and PTPI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and PTPI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
-2.21%
PTPI - ESPR
29%
Poorly correlated
+0.03%
ZOM - ESPR
26%
Poorly correlated
+2.53%
EVO - ESPR
26%
Poorly correlated
+1.73%
ALKS - ESPR
25%
Poorly correlated
-0.94%
VTRS - ESPR
25%
Poorly correlated
-0.35%
More

VTRS and

Correlation & Price change

A.I.dvisor tells us that VTRS and PRGO have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VTRS and PRGO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-0.35%
PRGO - VTRS
33%
Poorly correlated
-0.08%
AMRX - VTRS
31%
Poorly correlated
-0.60%
SNDL - VTRS
30%
Poorly correlated
-1.11%
ALKS - VTRS
29%
Poorly correlated
-0.94%
AMPH - VTRS
28%
Poorly correlated
+0.11%
More